Consensus outlines therapeutic approaches for hyperuricemia management in patients with high cardiovascular risk, emphasizing standardization.
This document updates previous documents of Russian Society of Hypertension and provides a condensed overview of the existing information. It aims to support healthcare professionals in developing optimal approaches to managing patients struggling with hyperuricemia and its related health conditions. Particular attention will be given to pointing to the need to standardize the definition of hyperuricemia and to hyperuricemia values associated with the risk of various cardiovascular diseases, paying attention to hyperuricemia in patients with chronic kidney disease.The present consensus regulates the prescription of uratelowering therapy depending on the severity of the detected hyperuricemia. Allopurinol continues to be the preferred initial choice for uric acid-lowering therapy in patients with high cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Blinova et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: